Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Disappointing FibroGen Pamrevlumab Trial Causes Trouble

Disappointing FibroGen Pamrevlumab Trial Causes Trouble

10th July 2023

There was a high level of anticipation surrounding FibroGen’s pamrevlumab trial outcomes. The chronic lung disease therapy was set to be a promising candidate, however study results proved to be underwhelming again, putting FibroGen in a highly vulnerable position.

Following the reports, their stocks plummeted by 82% from $16.05 to $2.86 over the course of a weekend.

Pamrevlumab was unable to prove that it could enhance patient performance for those with non-ambulatory DMD (Duchenne muscular dystrophy), creating yet another obstacle in the company’s path to success.

They now intend “to implement a significant cost reduction effort in the U.S.” so they can stretch funds to 2026. Their current resource was supposed to get them through until the end of next year, but by the end of March they began to experience financial difficulties, with under $400m available in cash.

They plan to terminate the next stages of their ZEPHYRUS study following disappointing stage 2 results. Although, they won’t be abandoning Pamrevlumab just yet, with a third stage trial projected to be carried out in Q3 this year; this one will focus on individuals suffering from ambulatory DMD.

The strategy for FibroGen is to “deepen our focus” on candidates in initial stages of development, submitting applications for human trials for a range of antibodies before the start of next year.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.